Please refer attachment

Results View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+9.4%Reaction day

₹37.25

prior close

₹37.31

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.4%+9.0% vs market

Commodity Chemicals peers, median of 51sector+0.0%+9.4% vs sector

On the reaction day the stock moved 9.0 pts more than Nifty Microcap 250 and 9.4 pts more than its Commodity Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.8

10m

-0.8

15m

-0.8

30m

+4.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+9.4+0.4+9.0+0.0+9.4

Next day

-0.3-2.3+1.9-3.2+2.9

-3.6-2.3-1.3-3.2-0.4

+0.3-2.4+2.7-3.2+3.5

-6.0-4.5-1.5-5.8-0.3

-7.0-4.6-2.4-4.8-2.2

-7.4-5.8-1.7-6.0-1.4

15d

-7.4+4.0-11.4-1.6-5.7

-6.1+6.1-12.1-0.2-5.9

-11.7+6.7-18.4+3.5-15.2

-12.2+11.4-23.6+4.3-16.5

UpDownMarket · Nifty Microcap 250Sector · Commodity Chemicals peers, median of 51Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The Board of Directors of Emmessar Biotech & Nutrition Ltd, at its meeting held on April 24, 2025, approved the audited standalone financial results for the year ended March 31, 2025. Revenue from Operations rose modestly to Rs. 61.09 lakhs from Rs. 55.52 lakhs in the previous year (~10% growth), while Total Income stood at Rs. 261.96 lakhs (vs Rs. 254.73 lakhs). Total expenses declined to Rs. 166.14 lakhs from Rs. 173.47 lakhs, helping Profit Before Tax grow to Rs. 95.82 lakhs (vs Rs. 81.26 lakhs). However, Net Profit after tax fell sharply to Rs. 31.61 lakhs (from Rs. 65.11 lakhs, ~51% decline) due to a much higher total tax expense of Rs. 64.20 lakhs. EPS dropped to Rs. 0.61 from Rs. 1.28. Statutory auditor V. Nagarajan & Co. issued an unmodified (clean) opinion. The company operates in two segments — Healthcare and Rent on leasehold land — and reported no investor complaints for the quarter.

Likely market impact

Operating performance improved (lower costs, higher PBT), but a sharp jump in tax burden cut net profit and EPS by more than half compared to last year. The clean auditor opinion is reassuring, but the steep PAT decline despite revenue growth is a negative signal for shareholders.